argenx SE
ARGX645.140USD
+15.629+2.48%
Cierre 04/30, 16:00（ET）Cotizaciones retrasadas 15 min
39.20BCap. mercado
47.06P/E TTM
Más Datos de argenx SE Compañía
argenx SE, formerly arGEN X BV, is a Netherlands-based biopharmaceutical company. It is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.
Información de la empresa
Código de la empresaARGX
Nombre de la empresaargenx SE
Fecha de salida a bolsaJul 10, 2014
Fundada en2008
Director ejecutivoMr. Tim van Hauwermeiren
Número de empleados1599
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 10
DirecciónLaarderhoogtweg 25
CiudadAMSTERDAM
Bolsa de valoresEuronext Brussels
PaísNetherlands
Código postal1101 EB
Teléfono31763030
Sitio Webhttps://www.argenx.com/
Código de la empresaARGX
Fecha de salida a bolsaJul 10, 2014
Fundada en2008
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Karl Gubitz
Mr. Karl Gubitz
Chief Financial Officer
Chief Financial Officer
500.00
--
Mrs. Camilla Sylvest
Mrs. Camilla Sylvest
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Tim van Hauwermeiren
Mr. Tim van Hauwermeiren
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
--
--
Dr. Ana Cespedes
Dr. Ana Cespedes
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Karen Massey
Ms. Karen Massey
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Joseph Donald (Don) debethizy, Ph.D.
Dr. Joseph Donald (Don) debethizy, Ph.D.
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Mrs. Andria Wilk
Mrs. Andria Wilk
Global Head of Quality
Global Head of Quality
--
--
Mr. Arjen Lemmen
Mr. Arjen Lemmen
Vice President - Corporate Development and Strategy
Vice President - Corporate Development and Strategy
--
--
Ms. Malini Moorthy
Ms. Malini Moorthy
General Counsel
General Counsel
--
--
Mr. Peter Ulrichts
Mr. Peter Ulrichts
Chief Scientific Officer
Chief Scientific Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Karl Gubitz
Mr. Karl Gubitz
Chief Financial Officer
Chief Financial Officer
500.00
--
Mrs. Camilla Sylvest
Mrs. Camilla Sylvest
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Tim van Hauwermeiren
Mr. Tim van Hauwermeiren
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
--
--
Dr. Ana Cespedes
Dr. Ana Cespedes
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Karen Massey
Ms. Karen Massey
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Joseph Donald (Don) debethizy, Ph.D.
Dr. Joseph Donald (Don) debethizy, Ph.D.
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Desglose de ingresos
Divisa: USDHora de actualización: dom., 6 de abr
Divisa: USDHora de actualización: dom., 6 de abr
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
United States
1.90B
86.56%
Rest of the World
161.25M
7.36%
Japan
89.39M
4.08%
China
43.52M
1.99%
Netherlands
153.00K
0.01%
Por negocio
Por región
Sin datos
Accionista
Hora de actualización: sáb., 26 de abr
Hora de actualización: sáb., 26 de abr
Estadísticas de accionistas
Tipo
Estadísticas de accionistas
Accionista
Proporción
Fidelity Management & Research Company LLC
8.87%
T. Rowe Price Associates, Inc.
7.71%
Artisan Partners Limited Partnership
5.03%
Janus Henderson Investors
3.79%
Capital World Investors
2.93%
Other
71.66%
Estadísticas de accionistas
Accionista
Proporción
Fidelity Management & Research Company LLC
8.87%
T. Rowe Price Associates, Inc.
7.71%
Artisan Partners Limited Partnership
5.03%
Janus Henderson Investors
3.79%
Capital World Investors
2.93%
Other
71.66%
Tipo
Accionista
Proporción
Investment Advisor
32.38%
Investment Advisor/Hedge Fund
17.28%
Hedge Fund
4.50%
Research Firm
1.80%
Pension Fund
0.51%
Private Equity
0.42%
Bank and Trust
0.07%
Other
43.05%
Participación institucional
Hora de actualización: dom., 19 de ene
Hora de actualización: dom., 19 de ene
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q1
775
34.82M
57.08%
-3.53M
2024Q4
769
34.65M
57.94%
-3.60M
2024Q3
721
35.68M
59.67%
-2.04M
2024Q2
693
34.77M
58.16%
-2.15M
2024Q1
675
34.54M
58.16%
-754.92K
2023Q4
655
33.23M
56.14%
-574.05K
2023Q3
612
32.76M
56.24%
+237.83K
2023Q2
559
31.23M
55.80%
-1.48M
2023Q1
539
31.55M
56.67%
-1.67M
2022Q4
531
31.27M
56.45%
-2.84M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Fidelity Management & Research Company LLC
5.41M
8.87%
+798.29K
+17.31%
Dec 31, 2024
T. Rowe Price Associates, Inc.
4.70M
7.71%
-292.11K
-5.85%
Dec 31, 2024
Artisan Partners Limited Partnership
3.07M
5.03%
-443.25K
-12.62%
Dec 31, 2024
Janus Henderson Investors
2.31M
3.79%
-166.85K
-6.73%
Dec 31, 2024
Capital World Investors
1.79M
2.93%
+86.69K
+5.10%
Dec 31, 2024
Avoro Capital Advisors LLC
1.24M
2.03%
--
--
Dec 31, 2024
T. Rowe Price International Ltd
813.71K
1.33%
-11.54K
-1.40%
Dec 31, 2024
RTW Investments L.P.
673.50K
1.1%
+19.07K
+2.91%
Dec 31, 2024
ClearBridge Investments, LLC
629.83K
1.03%
+40.33K
+6.84%
Dec 31, 2024
Bellevue Asset Management AG
593.18K
0.97%
-39.65K
-6.26%
Dec 31, 2024
Ver más
ETFs relacionados
Hora de actualización: dom., 6 de abr
Hora de actualización: dom., 6 de abr
Nombre
Proporción
Tema Neuroscience and Mental Health ETF
4.99%
VanEck Biotech ETF
4.9%
iShares Neuroscience and Healthcare ETF
4.31%
iShares Health Innovation Active ETF
3.47%
First Trust NYSE Arca Biotechnology Index Fund
2.96%
Goldman Sachs Future Health Care Equity ETF
2.4%
iShares Biotechnology ETF
2.32%
PGIM Jennison International Opportunities ETF
2.07%
Invesco Nasdaq Biotechnology ETF
1.93%
Harbor Health Care ETF
1.93%
Ver más
Tema Neuroscience and Mental Health ETF
Proporción4.99%
VanEck Biotech ETF
Proporción4.9%
iShares Neuroscience and Healthcare ETF
Proporción4.31%
iShares Health Innovation Active ETF
Proporción3.47%
First Trust NYSE Arca Biotechnology Index Fund
Proporción2.96%
Goldman Sachs Future Health Care Equity ETF
Proporción2.4%
iShares Biotechnology ETF
Proporción2.32%
PGIM Jennison International Opportunities ETF
Proporción2.07%
Invesco Nasdaq Biotechnology ETF
Proporción1.93%
Harbor Health Care ETF
Proporción1.93%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos